Kettering Cancer Center

Kettering, Ohio 45429

0 studies enrolling now · 3 studies all time

What they study most

Advanced Solid Tumor, BRAF Gene Alteration, BRAF Gene Mutation, MAP2K1 Gene Alteration, MAP2K1 Gene Mutation, MAP2K2 Gene Alteration, MAP2K2 Gene Mutation, MEK Alteration, MEK Mutation, Metastatic Castration Resistant Prostate Cancer, Platinum-resistant Ovarian Cancer

Studies at this site

• Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations — Stopped early
• Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed